HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Translational development of vaccination strategies in follicular NHL.

Abstract
Follicular lymphoma expresses a unique immunoglobulin molecule termed idiotype that has been used as a tumor-specific antigen for vaccine development. Early stage clinical studies revealed that vaccination consisting of keyhole limpet hemocyanin-conjugated lymphoma idiotype protein in combination with granulocyte-macrophage colony-stimulating factor induced tumor-specific immune responses and molecular remission in patients with follicular lymphoma. Three double-blind, randomized, Phase III trials were conducted to further determine the clinical benefit of this vaccine therapy. Compared to the placebo, prolonged disease-free survival in vaccinated patients was concluded only in one study where all the patients enrolled in the trial already had complete remission from induction chemotherapy. Next generation idiotype vaccines are being developed with the focus on simplifying vaccine formulation and potentiating tumor-specific immunity. This category includes genetically modified idiotype single-chain DNA vaccine, liposome-encapsulated idiotype vaccine and dendritic cell vaccine. Although preclinical data supported the immunogenicity and therapeutic advantage of these new vaccines, their clinical benefits remain to be tested. Optimizing new generation idiotype vaccines may require combination with immune adjuvants that potentiate vaccine-induced antitumor immunity, have direct effects against tumor or block immune regulatory checkpoints. Moreover, identification of a universal follicular lymphoma antigen is important for future development of vaccine therapy against this disease.
AuthorsIppei Sakamaki, Hong Qin, Larry W Kwak
JournalBest practice & research. Clinical haematology (Best Pract Res Clin Haematol) Vol. 24 Issue 2 Pg. 295-304 (Jun 2011) ISSN: 1532-1924 [Electronic] Netherlands
PMID21658625 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
CopyrightCopyright © 2011 Elsevier Ltd. All rights reserved.
Chemical References
  • Adjuvants, Immunologic
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • Cancer Vaccines
  • Immunoconjugates
  • Immunoglobulin Idiotypes
  • Liposomes
  • Vaccines, DNA
  • Rituximab
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Hemocyanins
  • keyhole-limpet hemocyanin
Topics
  • Adjuvants, Immunologic (pharmacology)
  • Animals
  • Antibodies, Monoclonal, Murine-Derived (administration & dosage)
  • Antigens, Neoplasm (immunology)
  • Antineoplastic Agents (administration & dosage)
  • B-Lymphocytes (drug effects, immunology, pathology)
  • Cancer Vaccines (immunology, therapeutic use)
  • Clinical Trials, Phase III as Topic
  • Disease-Free Survival
  • Granulocyte-Macrophage Colony-Stimulating Factor (immunology, pharmacology)
  • Hemocyanins (immunology, metabolism)
  • Humans
  • Immunoconjugates (chemistry, therapeutic use)
  • Immunoglobulin Idiotypes (chemistry, immunology)
  • Liposomes (immunology, pharmacology)
  • Lymphoma, Follicular (drug therapy, immunology, mortality, pathology)
  • Mice
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Remission Induction
  • Rituximab
  • Vaccination (methods)
  • Vaccines, DNA (immunology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: